The DOI matches its Crossref record.
Safety and efficacy of botulinum toxin type A following long‐term use
Abstract
Botulinum toxin serotype A (BoNT‐A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT‐A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT‐A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT‐A‐treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT‐A treatment. Long‐term BoNT‐A administration has been assessed in various treatment settings, with the level and duration of BoNT‐A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long‐term, repeated, multimuscle BoNT‐A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX®. These findings show long‐term BoNT‐A treatment to be both safe and efficacious for a wide variety of indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Aurora, S., Dodick, D., Turkel, C., DeGryse, R., Silberstein, S., Lipton, R., Diener, H., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364676 · Cited by 1,047
Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H., & Brin, M. F. (2010) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01678.x · Cited by 994
Diener, H., Dodick, D., Aurora, S., Turkel, C., DeGryse, R., Lipton, R., Silberstein, S., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364677 · Cited by 960
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology
Pirazzini, M., Rossetto, O., Eleopra, R., & Montecucco, C. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012658 · Cited by 768
European consensus table on the use of botulinum toxin type A in adult spasticity
Wissel, J., Ward, A., Erztgaard, P., Bensmail, D., Hecht, M., Lejeune, T., & Schnider, P. (2009) · Journal of Rehabilitation Medicine · doi:10.2340/16501977-0303 · Cited by 372
Metadata
- Authors
- Naumann, M., Albanese, A., Heinen, F., Molenaers, G., & Relja, M.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2006-11-13
- Volume
- 13
- Issue
- s4
- Pages
- 35-40
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2162210794
- Cited by
- 169
- References
- 0
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of botulinum toxin type A following long‐term use. https://app.cochat.ai/papers/10.1111/j.1468-1331.2006.01652.x
- The paper
- Naumann, M., Albanese, A., Heinen, F., Molenaers, G., & Relja, M. (2006). Safety and efficacy of botulinum toxin type A following long‐term use. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2006.01652.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.